Combined treatment with the glutaminase inhibitor CB-839 and PD-1 or cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-targeted therapy increased antigen-specific T-cell infiltration and inhibited tumor growth in a melanoma model11. Here, PDCD1 is linked to neoplasm.